Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gefurulimab - Alexion AstraZeneca Rare Disease

Next Previous
X
Search
Drug Profile

Gefurulimab - Alexion AstraZeneca Rare Disease

Alternative Names: ALXN-1720

Latest Information Update: 18 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alexion AstraZeneca Rare Disease
  • Class Bispecific antibodies; Recombinant fusion proteins; Single-domain antibodies
  • Mechanism of Action Complement C5 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myasthenia gravis
  • Phase I Proteinuria

Most Recent Events

  • 13 Nov 2024 Phase-III clinical trials in Myasthenia gravis (In children, In adolescents) in Taiwan (SC) (NCT06607627)
  • 28 Oct 2024 Alexion AstraZeneca Rare Disease initiates the phase I trial (In volunteers) in China (SC) (NCT06677138)
  • 28 Sep 2024 Alexion Pharmaceuticals completes a phase I trial in Healthy volunteers in Canada (SC) (NCT06208488)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top